Schaeffer's Top Stock Picks for '25

Sirius XM Can't Capitalize on Alexa, While Lipocine Shorts Shrug Off Drug Data

SIRI is holding steady above its 80-day after creating a double top on the charts earlier this month

Managing Editor
Jun 20, 2017 at 10:41 AM
facebook X logo linkedin


U.S. stocks are trading slightly lower this morning, after a strong performance yesterday. Among specific names on the move today are homebuilder Lennar Corporation (NYSE:LEN), satellite radio stock Sirius XM Holdings Inc. (NASDAQ:SIRI), and drugmaker Lipocine Inc (NASDAQ:LPCN). Here's a quick look at what's moving shares of LEN, SIRI, and LPCN.

Lennar Stock Jumps After Strong Profit and Guidance

Lennar stock is up 5% to trade at $55.23 -- near a new two-year high -- after the company's earnings report exceeded analysts' expectations. Today's rally is just more of the same for the homebuilder stock, which is up 28% year-to-date, and hit its previous annual high of $54.84 as recently as June 14. Since late 2016, the shares have been guided higher by their 50-day and 80-day moving averages.

Given the strong price action, it's no surprise to see analysts are upbeat on Lennar. Of the 12 brokerages covering LEN stock, seven rate it a "strong buy" or "buy."

Sirius XM Loses Pre-Market Momentum on Alexa News

Sirius XM stock is flat today at $5.24, with the stock unable to hold its pre-market gains following news that Alexa, Amazon's digital personal assistant, can now stream over 200 channels of SiriusXM satellite radio. SIRI stock has gained 18% year-to-date, but has lost some momentum since double-topping around $5.50 at the beginning of June. The stock's ensuing pullback has so far been supported by its 80-day moving average.

The options market isn't pricing in any big moves for Sirius stock anytime soon. SIRI has a Schaeffer's Volatility Index (SVI) of 22%, which ranks in the 7th annual percentile. This indicates that short-term options are pricing in significantly lower-than-usual volatility expectations.  

Lipocine Quickly Pares Post-Study Stock Gains

Lipocine stock is up 7.4% to trade at $4.32, after the company reported positive top-line results for LPCN 1021, its testosterone drug. Right out of the gate, LPCN rallied to an eight-month high of $5.14 -- near the site of its descending 320-day moving average -- but the stock has since pared those early gains considerably. This suggests the $4.50 level, site of the equity's year-to-date closing high, will continue to act as a technical ceiling.

Based on LPCN stock's rapid retreat from its morning highs today, it seems as though the shorts are firmly in control of this name. Short interest rose by 9% in the most recent reporting period to account for 13.3% of the security's float, or 10.8 times LPCN's average daily trading volume.

 
 

Which of These SUB-$5 Stocks Could 26x From Here? (AD)

He called a rare 11x on Tesla…

Then he called a 26x on Workhorse…

Then an even rarer 35x on Nio Inc…

Now Tim Bohen says these 5 tiny “America First” stocks are next up in 2025.

They’re trading for less than $5 right now.

But thanks to Elon & Trump’s new alliance…

They could be off to the races in Trump’s first 100 days.

And right now for a limited time…

You can get the names & tickers for just $1 here. (AD)

10 Stock Picks FREE
 
 

Featured Articles from Trusted Partners:

🚀 One Stock Pick Could Change Everything in 2025
What if one stock pick could define your success next year? Get 10 expert-vetted stocks set for 2025—plus 5 bonus picks to watch now. Get the Report →

🆕 New Options Need New Trading Strategies
Zero-DTE options are the newest (and hottest) options to trade.  Professional traders have rushed into the market and are making a mint.  Don’t get left behind - learn all about these options, how to trade them, market setups to profit from, plus much more. Download now →

👀 Revealed: 3 Defensive Stocks for Your Portfolio
Worried about the market? This free report reveals 3 under-the-radar defensive stocks for uncertain times in any kind of economy.

 

 
 

FREE Report Download

 

Follow us on X, Follow us on Twitter